OssDsign announced that 1,000 patients have been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
The product has been very well received in the U.S. market since its launch in 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000 patients.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022.
“OssDsign Catalyst is growing exponentially driven by a continuously growing customer base as well as broader usage within the hospitals and, in the last four months alone, we have doubled the number of patients treated. This is an outstanding development that highlights the potential for OssDsign Catalyst to become the preferred product for spinal fusion surgeries,” said Morten Henneveld, CEO of OssDsign.
OssDsign announced that 1,000 patients have been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
The product has been very well received in the U.S. market since its launch in 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000...
OssDsign announced that 1,000 patients have been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.
The product has been very well received in the U.S. market since its launch in 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000 patients.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022.
“OssDsign Catalyst is growing exponentially driven by a continuously growing customer base as well as broader usage within the hospitals and, in the last four months alone, we have doubled the number of patients treated. This is an outstanding development that highlights the potential for OssDsign Catalyst to become the preferred product for spinal fusion surgeries,” said Morten Henneveld, CEO of OssDsign.
Copy to clipboard 
